Novo Nordisk to Sell Semaglutide via Hims & Hers Telehealth Platform
Novo Nordisk has resolved its patent dispute with Hims & Hers, agreeing to distribute its semaglutide weight-loss drug through Hims & Hers’ telehealth platform. The partnership removes legal barriers and opens a direct-to-consumer channel expected to broaden market access for Novo Nordisk’s obesity treatment.
1. Legal Settlement
Novo Nordisk filed patent infringement claims over a compounded version of its semaglutide weight-loss drug and reached an agreement with Hims & Hers to drop all claims, resolving the dispute and clearing the way for commercial collaboration.
2. Distribution Partnership
Under the deal, Novo Nordisk will supply its semaglutide obesity treatment through Hims & Hers’ telehealth platform, enabling online prescribing and direct-to-consumer shipments without further legal restrictions.
3. Market Impact
The partnership opens a new sales channel for Novo Nordisk’s weight-loss drug, potentially accelerating patient acquisition in digital healthcare and complementing existing distributors to drive incremental volume growth.